-
公开(公告)号：US20170369525A1
公开(公告)日：2017-12-28
申请号：US15541020
申请日：2015-12-31
Applicant: Development Center for Biotechnology , DCB-USA LLC
Inventor： Chao-Pin Lee , Cheng-Chou Yu , Chi-Huey Wong , Chuan-Lung Hsu , Chun-Chung Lee , Shih-Hsien Chuang , Ta-Tung Yuan , Yi-Jen Chen , Yu-Chin Nieh
IPC: C07K1/107 , C07K1/08 , A61K39/395 , C07K16/18 , A61K47/68
CPC classification number: C07K1/1077 , A61K39/395 , A61K47/6803 , A61K47/6855 , A61K47/6889 , A61K49/0043 , A61K49/0058 , C07K1/08 , C07K16/18
Abstract: A method for specific linkage to a glycoprotein includes obtaining a glycoprotein having a monoglycan or diglycan attached thereto; producing a reactive functional group on a sugar unit on the glycoprotein; and coupling a linker or a payload to the reactive functional group on the glycoprotein.
-
公开(公告)号：US09447193B2
公开(公告)日：2016-09-20
申请号：US14223800
申请日：2014-03-24
Inventor： Alice L. Yu , John Yu , Ya-Hui Wang , Chuan-Lung Hsu , Yi-Chang Chen , Ying-Yung Lok
IPC: A61K39/395 , C07K16/30 , G01N33/574 , C12Q1/68
CPC classification number: C07K16/3015 , A61K39/39558 , C07K16/30 , C07K2317/55 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C12Q1/6886 , C12Q2600/158 , G01N33/57496
Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.
Abstract translation: 治疗癌症的方法包括向有需要的受试者施用针对跨膜和卷曲螺旋结构域蛋白3（TMCC3）的抗体，其中所述抗体结合TMCC3的细胞外结构域中的表位。 抗体结合TMCC3的线粒体结构域中的表位。 一种诊断或评估癌症病症的方法包括评估样品中跨膜和卷曲螺旋结构域蛋白3（TMCC3）的表达或活性水平，其中TMCC3的活性表达水平与 标准表明样品中存在癌干细胞。
-
公开(公告)号：US20180186884A1
公开(公告)日：2018-07-05
申请号：US15640935
申请日：2017-07-03
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： JIANN-SHIUN LAI , Li-Shuang Ai , Yan-Da Lai , Yen-Yu Wu , Yi-San Tsai , Yi-Jiue Tsai , Juo-Yu Huang , Cheng-Chou Yu , Chuan-Lung Hsu , Chien-Tsun Kuan , Szu-Liang Lai , Li-Ya Wang
IPC: C07K16/28 , G01N33/74 , C07K16/30 , A61K51/10 , A61K31/4439
CPC classification number: C07K16/2863 , A61K31/4439 , A61K47/6803 , A61K47/6849 , A61K51/1027 , A61K51/1096 , A61K2039/505 , A61K2039/507 , C07K14/71 , C07K16/005 , C07K16/2818 , C07K16/30 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/74 , G01N2333/71
Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.
-
公开(公告)号：US10138300B2
公开(公告)日：2018-11-27
申请号：US15640935
申请日：2017-07-03
Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
Inventor： Jiann-Shiun Lai , Li-Shuang Ai , Yan-Da Lai , Yen-Yu Wu , Yi-San Tsai , Yi-Jiue Tsai , Juo-Yu Huang , Cheng-Chou Yu , Chuan-Lung Hsu , Chien-Tsun Kuan , Szu-Liang Lai , Li-Ya Wang
IPC: C07K16/28 , C07K16/30 , G01N33/74 , A61K51/10 , A61K31/4439 , C07K14/71 , C07K16/00 , A61K47/68 , A61K47/48 , A61K39/00
Abstract: The present invention relates to an antibody or antigen-binding fragment thereof that bind human vascular endothelial growth factor receptor 2 (VEGFR-2). The present invention also relates to a method for inhibiting VEGFR-2-mediated signaling in a subject in need, a method for treating diseases and/or disorders caused by or related to VEGFR-2 activity and/or signaling in a subject afflicted with the diseases and disorders, a method for treating tumor in a subject afflicted with the tumor, a method for inhibiting cell proliferation of endothelial cells in a subject in need, and a method for detecting human vascular endothelial growth factor receptor in a sample.
-
Patent Agency Ranking
公开(公告)号：US20140363372A1
公开(公告)日：2014-12-11
申请号：US14223800
申请日：2014-03-24
Inventor： Alice L. Yu , John Yu , Ya-Hui Wang , Chuan-Lung Hsu , Yi-Chang Chen , Ying-Yung Lok
IPC: C07K16/30 , G01N33/574 , C12Q1/68 , A61K51/10
CPC classification number: C07K16/3015 , A61K39/39558 , C07K16/30 , C07K2317/55 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C12Q1/6886 , C12Q2600/158 , G01N33/57496
Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.
Abstract translation: 治疗癌症的方法包括向有需要的受试者施用针对跨膜和卷曲螺旋结构域蛋白3（TMCC3）的抗体，其中所述抗体结合TMCC3的细胞外结构域中的表位。 抗体结合TMCC3的线粒体结构域中的表位。 一种诊断或评估癌症病症的方法包括评估样品中跨膜和卷曲螺旋结构域蛋白3（TMCC3）的表达或活性水平，其中TMCC3的活性表达水平与 标准表明样品中存在癌干细胞。
-
公开(公告)号：US12202899B2
公开(公告)日：2025-01-21
申请号：US17256999
申请日：2019-07-14
Applicant: Development Center for Biotechnology
Inventor： Cheng-Chou Yu , Shih-Rang Yang , Tsung-Han Hsieh , Mei-Chi Chan , Shu-Ping Yeh , Chuan-Lung Hsu , Ling-Yueh Hu , Chih-Lun Hsiao
Abstract: An anti-PD-L1 antibody, or an antigen-binding fragment thereof, comprising: a heavy chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 2-4, 6-8, 10-12, 14-16, or 18-20; and/or a light chain variable region comprising the three CDRs with the sequences of SEQ ID NOs: 22-24, 26-28, 30-32, 34-36, or 38-40, wherein the antibody is a chimeric, humanized, composite, or human antibody.
-
公开(公告)号：US10947316B2
公开(公告)日：2021-03-16
申请号：US16010251
申请日：2018-06-15
Applicant: Development Center for Biotechnology
Inventor： Chao-Pin Lee , Shih-Hsien Chuang , Chuan-Lung Hsu , Yi-Jen Chen , Yu-Chin Nieh , Win-Yin Wei , Chia-Cheng Wu
IPC: A61P35/00 , A61K47/68 , A61K49/00 , G01N33/574 , A61K47/64 , A61K47/65 , A61K31/337 , A61K31/5365 , C07K16/30 , A61K39/395 , C07K16/28
Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab−(L−D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.
-
公开(公告)号：US20190330376A1
公开(公告)日：2019-10-31
申请号：US16475121
申请日：2017-12-29
Applicant: Development Center for Biotechnology
Inventor： Chen-Li Chien , Gregory Jiann Chen , Chuan-Lung Hsu , Jei-Hwa Yu , Hsien-Yu Tsai , Show-Shan Sheu , Wei-Jung Chang , Chia-Cheng Wu
IPC: C07K16/46 , C07K14/745
Abstract: A recombinant protein drug includes a parent protein drug coupled with a modified kininogen-1 peptide. The modified kininogen-1 peptide has the sequence of SEQ ID NO:2 or a homolog having a sequence identity of 80% or higher. The parent protein drug is a bispecific antibody having a first targeting domain linked by a bridging domain with a second targeting domain. The modified kininogen-1 peptide is fused between the first targeting domain and the bridging domain, or between the bridging domain and the second targeting domain. A method for increasing the serum half-life of a protein drug includes constructing a fusion protein comprising the protein drug coupled with a modified kininogen-1 peptide.
-
公开(公告)号：US20190106507A1
公开(公告)日：2019-04-11
申请号：US16010251
申请日：2018-06-15
Applicant: Development Center for Biotechnology
Inventor： Chao-Pin Lee , Shih-Hsien Chuang , Chuan-Lung Hsu , Yi-Jen Chen , Yu-Chin Nieh , Win-Yin Wei , Chia-Cheng Wu
Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab−(L−D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.015 seconds)
